Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia

Repeated cycles of post-remission high-dose cytarabine (Ara-C) have been suggested to improve survival in core binding factor (CBF) acute myeloid leukaemia (AML). High-dose Ara-C used for induction regimens has also been reported to be associated with increased treatment-related mortality (TRM). Few...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Biao, Zhang, Jihong, Hua, Xiaoying, Li, Haiqian, Wang, Zhilin, Yang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971028/
https://www.ncbi.nlm.nih.gov/pubmed/31959790
http://dx.doi.org/10.1038/s41598-020-57414-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971028/
https://www.ncbi.nlm.nih.gov/pubmed/31959790
http://dx.doi.org/10.1038/s41598-020-57414-y

Ejemplares similares